Document:

EX-10.21

 Exhibit 10.21 
  

 
 2 December 2014 

Rolf Stahel 
 Neatham 

Sleepers Hill 
 Winchester 

S022 4NB 
  

	RE:	New Amended Terms of Appointment 

 Dear Rolf, 

We hereby confirm that, with your agreement, the Terms of Appointment set out in the agreement between yourself and Midatech Limited dated 15 April 2014
(“Terms”) be and hereby transferred to Midatech Pharma PLC with immediate effect and with the following amendments: 
 The provisions of clause 3
(Restricted Shares) of the Terms be amended as follows regarding the provisions of the vesting criteria namely: 
  

	•	 	the reference in the Terms regarding the market capitalisation for the second and third tranches in relation to the Restricted Shares in Clause 3 shall be amended so that the words “on an Initial Public
Offering” are to be removed and replaced with the words “a target measured by the average market capitalisation on any public market over a 30 day period”, and that the trade sale and/or valuation measures, whilst subject to such
value hurdle, shall not require a 30 day period average. 

  

	•	 	the market capitalisation calculations shall be amended to refer to in the second tranche “subject to an increase in share price to at least 333 pence and with a market capitalisation of at least
£184.7m” and the third tranche amended to “subject to an increase in share price to at least 333 pence and with a market capitalisation of at least £240.9m”. 

In all other respects, save for the “Company” as defined in the Terms to be deemed to be a reference to Midatech Pharma PLC, the Terms shall
continue to have effect. 
  

	
	Yours sincerely,
	
	 /s/ Dr. James Phillips

	
	Director
	
	Midatech Parma PLC

 I agree to the terms set out above 
  

	
	 /s/ Rolf Stahel

	Rolf Stahel
	
	Dated December 2014
	
	The transfer of the Terms to Midatech Pharma PLC is agreed
	
	 /s/ Rolf Stahel

	Director - Midatech Limited
	
	Dated December 2014

  
 Page 2EX-10.22

 Exhibit 10.22 
  

			
	  
 PRIVATE AND CONFIDENTIAL

 
 [Individual’s Name]

[Address]
	  	

	  
	  

 — December 2014 

Dear [Individual], 
 Letter of appointment 

Following the recommendation of the nomination committee, the board of directors (the “Board”) of Midatech Pharma PLC (the
“Company”) has appointed you as [an independent] a non-executive director. 
 This letter sets out the main terms of your appointment. If
you are unhappy with any of the terms, or need any more information, please let me know. 
 By accepting this appointment, you agree that this letter is a
contract for services and is not a contract of employment and you confirm that you are not subject to any restrictions which prevent you from holding office as a director. 
  

	1	APPOINTMENT 

  

	1.1	Subject to the remaining provisions of this letter, your appointment shall be for an initial term of three years commencing on the date hereof unless terminated earlier by either party giving to the other one
month’s prior written notice. 

  

	1.2	Your appointment is subject to the Company’s articles of association, as amended from time to time (“Articles”). Nothing in this letter shall be taken to exclude or vary the terms of the Articles
as they apply to you as a director of the Company. Your appointment is subject to confirmation by the shareholders at the next AGM, and at any subsequent AGM as required by the Articles or as the Board resolves. 

 

	1.3	Continuation of your appointment is contingent on your continued satisfactory performance and re-election by the shareholders and any relevant statutory provisions relating to removal of a director. If the shareholders
do not re-elect you as a director, or you are retired from office under the Articles, your appointment shall terminate automatically, with immediate effect and without compensation. 

 

	1.4	Non-executive directors are typically expected to serve two three-year terms but may be invited by the Board to serve for an additional period. Any term renewal is subject to Board review and AGM re-election.
Notwithstanding any mutual expectation, there is no right to re-nomination by the Board, either annually or after any three-year period. 

  

	1.5	You may be required to serve on one or more Board committees. You will be provided with the relevant terms of reference on your appointment to such a committee. You also may be asked to serve as a non-executive director
on the 

  
 1 

	1.6	board of any of the Company’s subsidiaries or joint ventures, or as senior independent director. Any such appointment will be covered in a separate communication. 

 

	1.7	Notwithstanding paragraph 1.1 to paragraph 1.5, the Company may terminate your appointment with immediate effect if you have: 

  

	 	(a)	committed a material breach of your obligations under this letter; 

  

	 	(b)	committed any serious or repeated breach or non-observance of your obligations to the Company (which include an obligation not to breach your statutory, fiduciary or common-law duties); 

 

	 	(c)	been guilty of any fraud or dishonesty or acted in any manner which, in the Company’s opinion, brings or is likely to bring you or the Company into disrepute or is materially adverse to the Company’s
interests; 

  

	 	(d)	been convicted of an arrestable criminal offence other than a road traffic offence for which a fine or non-custodial penalty is imposed; 

 

	 	(e)	been declared bankrupt or have made an arrangement with or for the benefit of your creditors, or if you have a county court administration order made against you under the County Court Act 1984; 

 

	 	(f)	been disqualified from acting as a director; or 

  

	 	(g)	not complied with the Company’s anti-corruption and bribery policy and procedures, from time to time, or the Bribery Act 2010. 

  

	1.8	On termination of your appointment, you shall, at the Company’s request, resign from your office as director of the Company and any offices you hold in any of the Company’s group companies. 

 

	1.9	If matters arise which cause you concern about your role, you should discuss these matters with the chairman. If you have any concerns which cannot be resolved, and you choose to resign for that, or any other, reason,
you should provide an appropriate written statement to the chairman for circulation to the Board. 

  

	2	TIME COMMITMENT 

  

	2.1	You will be expected to devote such time as is necessary for the proper performance of your duties. Overall we anticipate that you will spend a minimum of 4 days a month on work for the Company. This is likely to
include attendance at Board meetings, the AGM, one annual Board away day a year, at least one site visit a year, meetings with the non-executive directors, meetings with shareholders, meetings forming part of the Board evaluation process and
updating and training meetings. Some of these meetings may involve overseas travel. In addition, you will be required to consider all relevant papers before each meeting. Unless urgent and unavoidable circumstances prevent you from doing so, it is
expected that you will attend the meetings outlined in this paragraph. 

  

	2.2	The nature of the role makes it impossible to be specific about the maximum time commitment. You may be required to devote additional time to the Company in respect of preparation time and ad hoc matters which may arise
and particularly when the Company is undergoing a period of increased activity. At certain times it may be necessary to convene additional Board, committee or shareholder meetings. 

  
 2 

	2.3	The overall time commitment stated in paragraph 2.1 will increase if you become a committee member or chair, or if you are given additional responsibilities, such as being appointed the senior independent director, or
non-executive director on the boards of any of the Company’s subsidiaries. Details of the expected increase in time commitment will be covered in any relevant communication confirming the additional responsibility. 

 

	2.4	By accepting this appointment, you confirm that, taking into account all of your other commitments, you are able to allocate sufficient time to the Company to discharge your responsibilities effectively. You should
obtain the agreement of the chairman before accepting additional commitments that might affect the time you are able to devote to your role as a non-executive director of the Company. 

 

	3	ROLE AND DUTIES 

  

	3.1	The Board as a whole is collectively responsible for the success of the Company. The Board’s role is to: 

  

	 	(a)	provide entrepreneurial leadership of the Company within a framework of prudent and effective controls which enable risk to be assessed and managed; 

 

	 	(b)	set the Company’s strategic aims, ensure that the necessary financial and human resources are in place for the Company to meet its objectives, and review management performance; and 

 

	 	(c)	set the Company’s values and standards and ensure that its obligations to its shareholders and others are understood and met. 

  

	3.2	As a non-executive director you shall have the same general legal responsibilities to the Company as any other director. You are expected to perform your duties (whether statutory, fiduciary or common law) faithfully,
diligently and to a standard commensurate with the functions of your role and your knowledge, skills and experience. 

  

	3.3	You shall exercise your powers in your role as a non-executive director having regard to relevant obligations under prevailing law and regulation, including the Companies Act 2006, the UK Corporate Governance Code and
associated guidance, the UK Listing Authority’s Listing, Prospectus, and Disclosure and Transparency Rules. 

  

	3.4	You shall have particular regard to the general duties of directors in Part 10 of the Companies Act 2006, including the duty to promote the success of the Company under which all directors must act in the way they
consider, in good faith, would be most likely to promote the success of the Company for the benefit of its members as a whole. In doing so, as a director, you must have regard (among other matters) to: 

 

	 	(a)	the likely consequences of any decision in the long term; 

  

	 	(b)	the interests of the Company’s employees; 

  

	 	(c)	the need to foster the Company’s business relationships with suppliers, customers and others; 

  

	 	(d)	the impact of the Company’s operations on the community and the environment; 

  
 3 

	 	(e)	the desirability of the Company maintaining a reputation for high standards of business conduct; and 

  

	 	(f)	the need to act fairly as between the members of the Company. 

  

	3.5	You shall have particular regard to the Financial Reporting Council’s UK Corporate Governance Code and associated Guidance on Board Effectiveness in respect of the role of the Board and the role of the
non-executive director. 

  

	3.6	In your role as a non-executive director, you shall also be required to: 

  

	 	(a)	constructively challenge and help develop proposals on strategy; 

  

	 	(b)	scrutinise the performance of management in meeting agreed goals and objectives and monitor the reporting of performance; 

  

	 	(c)	satisfy yourself on the integrity of financial information and that financial controls and systems of risk management are robust and defensible; 

 

	 	(d)	be responsible for determining appropriate levels of remuneration of executive directors and have a prime role in appointing and, where necessary, removing senior management and in succession planning;

  

	 	(e)	devote time to developing and refreshing your knowledge and skills; 

  

	 	(f)	uphold high standards of integrity and probity and support the chairman and executive directors in instilling the appropriate culture, values and behaviours in the boardroom and beyond; 

 

	 	(g)	insist on receiving high-quality information sufficiently in advance of Board meetings; 

  

	 	(h)	take into account the views of shareholders and other stakeholders where appropriate; 

  

	 	(i)	make sufficient time available to discharge your responsibilities effectively; 

  

	 	(j)	exercise relevant powers under, and abide by, the Articles; 

  

	 	(k)	disclose the nature and extent of any direct or indirect interest you may have in any matter being considered at a Board or committee meeting and, except as permitted under the Articles you will not vote on any
resolution of the Board, or of one of its committees, on any matter where you have any direct or indirect interest; 

  

	 	(l)	immediately report your own wrongdoing or the wrongdoing or proposed wrongdoing of any employee or other director of the Company of which you become aware to the Chairman; 

 

	 	(m)	exercise your powers as a director in accordance with the Company’s policies and procedures and internal control framework, from time to time, and the Bribery Act 2010; and 

 

	 	(n)	not do anything that would cause you to be disqualified from acting as a director. 

  

	3.7	Unless the Board specifically authorises you to do so, you shall not enter into any legal or other commitment or contract on behalf of the Company. 

 

	3.8	You shall be entitled to request all relevant information about the Company’s affairs as is reasonably necessary to enable you to discharge your responsibilities as a non-executive director. 

  
 4 

	4	FEES AND EXPENSES 

  

	4.1	You shall be paid an annual fee of £35,000 gross (current at the date of this letter), which shall be paid in equal instalments monthly in arrears through PAYE after deduction of any taxes and other amounts that
are required by law, which shall be subject to an periodic review by the Board. This fee covers all duties, including service on any Board committee or Company subsidiary, with the exception of committee chairmanships and certain additional
responsibilities, such as taking on the role of senior independent director. 

  

	4.2	The Company shall reimburse you for all reasonable and properly documented expenses that you incur in performing the duties of your office. The procedure and other guidance in respect of expense claims is available from
the Chairman. 

  

	4.3	On termination of your appointment, you shall only be entitled to such fees as may have accrued to the date of termination, together with reimbursement in the normal way of any expenses properly incurred before that
date. 

  

	5	INDEPENDENT PROFESSIONAL ADVICE 

 In some circumstances you may consider that you need
professional advice in the furtherance of your duties as a director and it may be appropriate for you to seek advice from independent advisers at the Company’s expense. A copy of the Board’s agreed procedure under which directors may
obtain such independent advice is available from the Chairman. The Company shall reimburse the reasonable cost of expenditure incurred by you in accordance with its policy. 
  

	6	OUTSIDE INTERESTS 

  

	6.1	You have already disclosed to the Board the significant commitments you have outside your role in the Company. You must inform the chairman in advance of any changes to these commitments. In certain circumstances, you
may have to seek the Board’s agreement before accepting further commitments which either might give rise to a conflict of interest or a conflict with any of your duties to the Company, or which might impact on the time that you are able to
devote to your role at the Company. 

  

	6.2	It is accepted and acknowledged that you have business interests other than those of the Company and have declared any conflicts that are apparent at present. If you become aware of any further potential or actual
conflicts of interest, these should be disclosed to the chairman and company secretary as soon as you become aware of them and again you may have to seek the agreement of the Board. 

 

	7	CONFIDENTIALITY 

  

	7.1	You acknowledge that all information acquired during your appointment is confidential to the Company and should not be released, communicated or disclosed to third parties or used for any reason other than in the
interests of the Company, either during your appointment or following termination (by whatever means), without prior clearance from the chairman. This restriction shall cease to apply to any confidential information which may (other than by reason
of your breach) become available to the public generally. 

  
 5 

	7.2	You acknowledge the need to hold and retain Company information (in whatever format you may receive it) under appropriately secure conditions. 

 

	7.3	Nothing in this paragraph 7 shall prevent you from disclosing information which you are entitled to disclose under the Public Interest Disclosure Act 1998, provided that the disclosure is made in accordance with the
provisions of that Act and you have complied with the Company’s policy from time to time in force regarding such disclosures. 

  

	8	INSIDE INFORMATION AND DEALING IN THE COMPANY’S SHARES 

  

	8.1	Your attention is drawn to the requirements under both law and regulation as to the disclosure of inside information, in particular to the Disclosure and Transparency Rules of the UK Listing Authority and section 52 of
the Criminal Justice Act 1993 on insider dealing. You should avoid making any statements that might risk a breach of these requirements. If in doubt, please contact the chairman or company secretary. 

 

	8.2	During your period of appointment you are required to comply with the provisions of the Model Code (as annexed to the Listing Rules of the UK Listing Authority) in relation to dealing in the Company’s publicly
traded or quoted securities, and any such other code as the Company may adopt from time to time which sets out the terms for dealings by directors in the Company’s publicly traded or quoted securities. A copy of the current share dealing code
adopted by the Company is will be provided to you separately. 

  

	9	TRAINING 

 On an ongoing basis, and further to the annual evaluation process, the Company
will arrange for you to develop and refresh your skills and knowledge in areas which are mutually identified as being likely to be required, or of benefit to you, in carrying out your duties effectively. You should try to make yourself available for
any relevant training sessions which may be organised for the Board. 
  

	10	REVIEW PROCESS 

 The performance of individual directors and the whole Board and its
committees is evaluated annually. If, in the interim, there are any matters which cause you concern about your role you should discuss them with the chairman as soon as you can. 

 

	11	INSURANCE AND INDEMNITY 

  

	11.1	The Company has directors’ and officers’ liability insurance and it intends to maintain such cover for the full term of your appointment. A copy of the policy document is available from the Chairman.

  

	11.2	The Company shall grant you a deed of indemnity against certain liabilities that may be incurred as a result of your office to the extent permitted by section 234 of the Companies Act 2006. 

 

	12	CHANGES TO PERSONAL DETAILS 

 You shall advise the company secretary promptly of any
change in your address or other personal contact details. 

  
 6 

	13	RETURN OF PROPERTY 

 On termination of your appointment with the Company however arising,
or at any time at the Board’s request, you shall immediately return to the Company all documents, records, papers or other property belonging to the Company or any company in the Company’s group, as applicable, which may be in your
possession or under your control, and which relate in any way to the Company’s or a group company’s business affairs, as applicable, and you shall not retain any copies thereof. 

 

	14	MORAL RIGHTS 

 You hereby irrevocably waive any moral rights in all works prepared by
you, in the provision of your services to the Company, to which you are now or may at any future time be entitled under Chapter IV of the Copyright Designs and Patents Act 1988 or any similar provisions of law in any jurisdiction, including (but
without limitation) the right to be identified, the right of integrity and the right against false attribution, and agree not to institute, support, maintain or permit any action or claim to the effect that any treatment, exploitation or use of such
works or other materials, infringes your moral rights. 
  

	15	POST-TERMINATION RESTRICTION 

 By countersignature of this letter and in consideration
for the fees payable to you under the terms of this letter, you agree that, in order to protect the confidential information, trade secrets and business connections of the Company and each company in the Company’s group, as applicable, to which
you have access as a result of your appointment, you will not (without the previous consent in writing of the Company), for the period of 6 months immediately after the termination of your appointment, whether as principal or agent and whether alone
or jointly with, or as a director, manager, partner, shareholder, employee consultant of, any other person, carry on or be engaged, concerned or interested in any business which is similar to or which is (or intends to be) in competition with any
business being carried on by the Company or any company in the Company’s group, as applicable. 
  

	16	DATA PROTECTION 

  

	16.1	By signing this letter you consent to the Company holding and processing data about you for legal, personnel, administrative and management purposes and in particular to the processing of any sensitive personal
data (as defined in the Data Protection Act 1998) relating to you including, as appropriate: 

  

	 	(a)	information about your physical or mental health or condition in order to monitor sick leave and take decisions as to your fitness to perform your duties; or 

 

	 	(b)	your racial or ethnic origin or religious or similar beliefs in order to monitor compliance with equal opportunities legislation; or 

 

	 	(c)	information relating to any criminal proceedings in which you have been involved for insurance purposes and in order to comply with legal requirements and obligations to third parties. 

You consent to the Company making such information available to any of its group companies, those who provide products or services to the
Company or any company in the Company’s group (such as advisers and payroll administrators), 

  
 7 

 
regulatory authorities, potential or future employers, governmental or quasi-governmental organisations and potential purchasers of the Company or the business in which you work. 

 

	16.2	You also consent to the transfer of such information to the Company’s or any group company’s business contacts outside the European Economic Area in order to further their business interests even where the
country or territory in question does not maintain adequate data protection standards. 

  

	16.3	You shall comply with the Company’s data protection policy, a copy of which is available from the Chairman. 

  

	16.4	The Company may change its data protection policy at any time and will notify you in writing of any changes. 

  

	17	THIRD PARTY RIGHTS 

 No one other than you and the Company shall have any rights to
enforce the terms of this letter. 
  

	18	ENTIRE AGREEMENT 

  

	18.1	This letter and any document referred to in it constitutes the entire terms and conditions of your appointment and supersedes and extinguishes all previous agreements, promises, assurances, warranties, representations
and understandings between you and the Company, whether written or oral, relating to its subject matter. 

  

	18.2	You agree that you shall have no remedies in respect of any representation, assurance or warranty (whether made innocently or negligently) that is not set out in this letter and you shall not have any claim for innocent
or negligent misrepresentation or negligent misstatement based on any statement in this letter. 

  

	19	VARIATION 

 No variation of this letter shall be effective unless it is in writing and
signed by you and the Company (or respective authorised representatives). 
  

	20	GOVERNING LAW AND JURISDICTION 

 Your appointment with the Company and any dispute or
claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the law of England and Wales and you and the Company irrevocably
agree that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this appointment or its subject matter or formation (including non-contractual disputes or claims).

 Please indicate your acceptance of these terms by signing and returning the attached copy of this letter to the Chairman. 

 

	
	Yours sincerely
	
	  

	
	For and on behalf of MIDATECH PHARMA PLC

  
 8 

	
	Director

 I confirm and agree to the terms of my appointment as a non-executive director of Midatech Pharma PLC as set out in this
letter. 
  

	
	Signed on      December 2014
	
	  

  
 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]